NEW YORK (GenomeWeb News) – Trovagene said this week that it will collaborate with researchers at the University of Texas MD Anderson Cancer Center on detecting transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. The researchers will use Trovagene's transrenal DNA detection technology to evaluate BRAF mutation status in urine compared to tissue biopsy. The partners previously collaborated on detecting transrenal KRAS mutations in the urine of patients with pancreatic cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.